cisapride has been researched along with Colitis, Mucous in 9 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies with cisapride reported conflicting results in patients with constipation-predominant irritable bowel syndrome (IBS)." | 9.11 | Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. ( Kruis, W; Ziegenhagen, DJ, 2004) |
| "Cisapride is a propulsive agent, withdrawn from most of the world's health institutes because of its recorded fatalities in addition to serious side effects such as severe arrhythmias." | 8.87 | Cisapride for intestinal constipation. ( Aboumarzouk, OM; Agarwal, T; Antakia, R; Nelson, RL; Shariff, U, 2011) |
| "Previous studies with cisapride reported conflicting results in patients with constipation-predominant irritable bowel syndrome (IBS)." | 5.11 | Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. ( Kruis, W; Ziegenhagen, DJ, 2004) |
| "Cisapride is a propulsive agent, withdrawn from most of the world's health institutes because of its recorded fatalities in addition to serious side effects such as severe arrhythmias." | 4.87 | Cisapride for intestinal constipation. ( Aboumarzouk, OM; Agarwal, T; Antakia, R; Nelson, RL; Shariff, U, 2011) |
| " Problems have arisen with alosetron being associated with ischaemic colitis and a high incidence of constipation." | 4.81 | Pharmacological treatment of irritable bowel syndrome--from concept to sales. ( Kamm, MA, 2002) |
| "The aim of this study was to assess the cardiovascular effect of MA-2029, a selective motilin receptor antagonist highly expected for the treatment of irritable bowel syndrome (IBS)." | 3.74 | Cardiovascular safety profile of MA-2029, a novel motilin receptor antagonist. ( Honda, M; Itoh, M; Kimura, K; Komatsu, R; Tabo, M, 2008) |
| "The total effective rate and recurrence rate of the treated group were superior to those of the control group significantly (P < 0." | 2.71 | Effect of modified Sinisan on anorectal manometry of the constipation predominant type of irritable bowel syndrome. ( Chen, G; Ding, SQ; Ha, NL; Ye, H; Yu, SP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hamatani, T | 1 |
| Noda, N | 1 |
| Takagaki, T | 1 |
| Yodo, Y | 1 |
| Kawai, H | 1 |
| Kakuyama, H | 1 |
| Kaji, Y | 1 |
| Fujio, Y | 1 |
| Li, DY | 1 |
| Dai, YK | 1 |
| Zhang, YZ | 1 |
| Huang, MX | 1 |
| Li, RL | 1 |
| Ou-Yang, J | 1 |
| Chen, WJ | 1 |
| Hu, L | 1 |
| Tabo, M | 1 |
| Komatsu, R | 1 |
| Honda, M | 1 |
| Itoh, M | 1 |
| Kimura, K | 1 |
| Aboumarzouk, OM | 1 |
| Agarwal, T | 1 |
| Antakia, R | 1 |
| Shariff, U | 1 |
| Nelson, RL | 1 |
| Olden, KW | 1 |
| Ziegenhagen, DJ | 1 |
| Kruis, W | 1 |
| Yu, SP | 1 |
| Ye, H | 1 |
| Ha, NL | 1 |
| Ding, SQ | 1 |
| Chen, G | 1 |
| Kamm, MA | 1 |
| Rösch, W | 1 |
| Liebregts, T | 1 |
| Gundermann, KJ | 1 |
| Vinson, B | 1 |
| Holtmann, G | 1 |
4 reviews available for cisapride and Colitis, Mucous
| Article | Year |
|---|---|
Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome.
Topics: Benzamides; Cisapride; Constipation; Humans; Irritable Bowel Syndrome; Medicine, Chinese Traditional | 2017 |
Cisapride for intestinal constipation.
Topics: Adult; Arrhythmias, Cardiac; Child; Cisapride; Constipation; Female; Gastrointestinal Agents; Humans | 2011 |
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Topics: Antidepressive Agents; Benzofurans; Carbolines; Cisapride; Constipation; Drug Industry; Gastrointest | 2002 |
Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5.
Topics: Antiemetics; Cisapride; Cohort Studies; Double-Blind Method; Dyspepsia; Gastrointestinal Agents; Hum | 2006 |
3 trials available for cisapride and Colitis, Mucous
| Article | Year |
|---|---|
Thorough QT/QTc Study Shows That a Novel 5-HT
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; | 2020 |
Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo.
Topics: Adolescent; Adult; Aged; Cisapride; Constipation; Female; Gastrointestinal Agents; Humans; Irritable | 2004 |
Effect of modified Sinisan on anorectal manometry of the constipation predominant type of irritable bowel syndrome.
Topics: Adult; Aged; Anal Canal; Cisapride; Constipation; Female; Follow-Up Studies; Gastrointestinal Agents | 2005 |
2 other studies available for cisapride and Colitis, Mucous
| Article | Year |
|---|---|
Cardiovascular safety profile of MA-2029, a novel motilin receptor antagonist.
Topics: Action Potentials; Animals; Blood Pressure; Cell Line; Cisapride; Dogs; Electric Stimulation; Electr | 2008 |
Therapy for irritable bowel syndrome.
Topics: Antidepressive Agents; Cisapride; Female; Humans; Indoles; Irritable Bowel Syndrome; Serotonin 5-HT3 | 2004 |